Beam Therapeutics Inc.
$31.01+0.4%YTD+11.2%1Y+45.9%
Mentions · last 7 days
457+10%
Price updated 15m ago·X counts updated 21h ago
AI verdict & sentimentAI analysisGenerated by AI from underlying data
Today's AI verdict on what's driving $BEAM, plus how loud the X conversation is and which way it's leaning.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $BEAM.
Biotechnology
No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.
What this means for $BEAM
Partial — Develops base-editing gene medicines making precise single-letter DNA corrections for blood disorders and genetic diseases; the GLP-1 pipeline bifurcation and ADA oral formulation competition creates tailwinds for one product line, not the full operation.
Top industry ETF
$IBBiShares Biotechnology ETF
+11.2%YTD
+43.1%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-46.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
-26.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
-227%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-12.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
18.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-5.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
-32.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.91$-0.87-4.6%
Q4 2025Feb 24, 2026$-0.10$-1.13+91.2%
Q3 2025Nov 4, 2025$-1.10$-0.98-12.2%
Q2 2025Aug 5, 2025$-1.00$-1.04+3.8%
Next earningsTue, Aug 4·consensus EPS $-1.11
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$31.7M+324.9%100%-338%$-0.91$-130.7M
Q4 FY25$114.1M+279.5%95.0%-15.3%$2.37$-87.0M
Q3 FY25$9.7M-32.0%-1032%-1308%$-1.10$-86.5M
Q2 FY25$8.5M-28.1%-1102%-1419%$-1.00$-79.6M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$78.5M$73.0M – $81.2M-$4.40-$4.85 – -$4.0110
FY27$87.7M$80.6M – $92.9M-$4.56-$5.21 – -$4.159
FY28$152.3M$151.8M – $152.9M-$4.43-$7.54 – -$2.9611
FY29$416.8M$301.6M – $623.1M-$3.18-$5.23 – -$2.045
FY30$873.8M$632.4M – $1.3B-$0.69-$1.13 – -$0.445
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.67%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-2.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+10.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 93.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.2% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β2.185-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KShareholder voteJun 88-K — Item 5.07: Shareholder vote
AI summary
8-KAgreement terminatedMar 58-K — Item 1.02: Agreement terminated
8-KMaterial agreementFeb 248-K — Item 1.01: Material agreement · Item 2.02: Earnings release · Item 2.03: Material debt obligation
8-KMaterial agreementFeb 128-K — Item 1.01: Material agreement
8-KOfficer or director changeFeb 58-K — Item 5.02: Officer or director change
+ 13 other (6 13Gs · 2 proxys · 1 10-Q · 1 earnings 8-K) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are InvestablePrime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics CaseA New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR TherapeuticsPowder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster SqueezeBEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
In themes
Explore the broader themes this ticker is being talked about under.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 10 · last 7 days